Polymun Scientific
Founded in 1992; offers biologics and liposome/LNP development and manufacturing, with an officially disclosed Austrian pharmaceutical manufacturing authorization.
AustriaFull profile →
Find your next research lead.
All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
471 company identities · 13 technology & service fields
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
51 matching companies
Genevant Sciences
Focuses on nucleic acid delivery platforms and intellectual property licensing; its LNP technology supports partner mRNA, RNA editing, and in vivo CAR-T programs.
CanadaFull profile →
ST PHARM
Offers IVT mRNA-LNP development and manufacturing, with SMARTCAP capping and STLNP delivery technologies.
South KoreaFull profile →
Merck KGaA, Darmstadt, Germany
The life science business of Germany's Merck KGaA offers mRNA, lipid, LNP, fill-finish, and testing services. It is separate from U.S.-based Merck & Co. / MSD.
GermanyFull profile →
RIBOPRO
Offers mRNA design, manufacturing, and LNP formulation, with disclosed partner work on tissue- and cell-targeted delivery.
NetherlandsFull profile →
Curapath
Offers lipid- and polymer-based nonviral delivery systems, LNP/PNP formulation optimization, and manufacturing for mRNA and other nucleic acid payloads.
SpainFull profile →
Kaneka Eurogentec
Offers mRNA production services. In 2025 the company announced Belgian regulatory approval of an expanded mRNA manufacturing facility for late-stage clinical and commercial production.
BelgiumFull profile →
CATUG Biotechnology
Founded in 2021, the company offers DNA, RNA, LNP/tLNP, analytical, and GMP manufacturing services for advanced-therapy CMC development.
ChinaFull profile →
Hongene Biotech Corporation
Offers mRNA DNA templates, IVT and HiXCap capping, purification, LNP formulation, and aseptic fill-finish, and supplies nucleic acid raw materials.
ChinaFull profile →
GenScript / ProBio
GenScript's life science business offers IVT RNA and LNP-related services. Its ProBio subsidiary provides CGT CMC services including mRNA vaccines and nucleic acid drugs. Entity information uses GenScript group-level data.
United States / ChinaFull profile →
FUJIFILM Toyama Chemical
The Toyama site in Japan offers integrated GMP mRNA production, LNP formulation, and fill-finish. It is distinct from FUJIFILM Biotechnologies (formerly Diosynth).
JapanFull profile →
Thermo Fisher Scientific
Offers mRNA development and manufacturing, with co-located mRNA, LNP, and fill-finish capabilities supporting RNA drug supply.
United StatesFull profile →
CordenPharma
Offers LNP development and manufacturing for mRNA and other biological payloads, using processes including microfluidics, impingement mixing, filtration, and concentration.
GermanyFull profile →
Touchlight
Founded in 2007, the company offers cell-free enzymatic dbDNA templates for mRNA and other genetic medicines. This is an upstream template service, not equivalent to an mRNA-LNP drug product CDMO.
United KingdomFull profile →
Recipharm
Offers xRNA and LNP services, including mRNA drug substance, LNPs, and ATMP fill-finish. The current provider, brand, and manufacturing site require confirmation.
SwedenFull profile →
Daiichi Sankyo
In 2023 Daiichi Sankyo announced Japanese approval of its DAICHIRONA (DS-5670) mRNA COVID-19 vaccine. The approved product should be evaluated separately from other newer programs.
JapanFull profile →
SK bioscience
The company's first mRNA Japanese encephalitis vaccine, GBP560, entered Phase 1/2 trials in Australia and New Zealand. It is distinct from its existing non-mRNA vaccines.
South KoreaFull profile →
Stemirna Therapeutics
A historical partner page describes Stemirna's mRNA vaccine and nanolipid/polymer delivery R&D. The company's website was inaccessible during this review; current operations and clinical status remain unverified.
ChinaFull profile →
Yunxin Zhili
Yunxin Zhili is a Hangzhou-based service provider supporting process development, manufacturing, and CMC activities for advanced therapies. Its official materials describe plasmid and mRNA services spanning sequence and template preparation, RNA production, purification, LNP formulation, and testing, with targeted LNP development also listed. Manufacturing grade, project scale, timelines, and regulatory suitability require project-specific confirmation.
ChinaFull profile →
Levostar Biotech
Levostar Biotech, based in Suzhou, supports nucleic acid and cell and gene therapy projects with plasmid services, RNA synthesis and delivery development, and analytical testing. Its mRNA offering includes sequence design, template construction, RNA production, and LNP formulation. The targeted LNP platform describes antibody conjugation and particle characterization. Manufacturing grade and suitability for a clinical regulatory submission must be confirmed for each project.
ChinaFull profile →
Orna Therapeutics
Develops circular RNA (oRNA) and LNP delivery. Its current LinkedIn page identifies it as a wholly owned Eli Lilly subsidiary, so it should not be treated as an independent private platform company.
United StatesFull profile →
Orbital Therapeutics
An RNA and in vivo immune reprogramming platform developer; the website identifies it as a Bristol Myers Squibb company.
United StatesFull profile →
Strand Therapeutics
STX-001 is an intratumoral self-replicating mRNA treatment encoding IL-12. The company discloses a Phase 1 study and a broader programmable RNA platform.
United StatesFull profile →
Immorna
Founded in 2019, the company develops mRNA, self-replicating RNA, and delivery platforms. In 2026 it reported early JCXH-213 results in two patients with ITP; these findings should be distinguished from formal registered-trial phases and independent validation.
ChinaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.